JP2017535546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535546A5 JP2017535546A5 JP2017525839A JP2017525839A JP2017535546A5 JP 2017535546 A5 JP2017535546 A5 JP 2017535546A5 JP 2017525839 A JP2017525839 A JP 2017525839A JP 2017525839 A JP2017525839 A JP 2017525839A JP 2017535546 A5 JP2017535546 A5 JP 2017535546A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- prodrug
- formula
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 1093
- 150000003839 salts Chemical class 0.000 claims description 526
- 239000000651 prodrug Substances 0.000 claims description 483
- 229940002612 prodrug Drugs 0.000 claims description 478
- 239000000243 solution Substances 0.000 claims description 180
- 210000000056 organ Anatomy 0.000 claims description 141
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 110
- 102000010637 Aquaporins Human genes 0.000 claims description 105
- 108010063290 Aquaporins Proteins 0.000 claims description 104
- -1 N, N-disubstituted carbamoyl group Chemical group 0.000 claims description 99
- 206010052779 Transplant rejections Diseases 0.000 claims description 96
- 238000002054 transplantation Methods 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 84
- 239000003112 inhibitor Substances 0.000 claims description 84
- 210000002216 heart Anatomy 0.000 claims description 75
- 210000001519 tissue Anatomy 0.000 claims description 73
- 229940121720 Aquaporin inhibitor Drugs 0.000 claims description 61
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 57
- 239000012620 biological material Substances 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000001246 bromo group Chemical group Br* 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 37
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 34
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000002252 acyl group Chemical group 0.000 claims description 26
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 26
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 238000007675 cardiac surgery Methods 0.000 claims description 21
- 210000004698 lymphocyte Anatomy 0.000 claims description 21
- 210000004153 islets of langerhan Anatomy 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 13
- 210000003734 kidney Anatomy 0.000 claims description 13
- 210000004072 lung Anatomy 0.000 claims description 13
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 13
- 229960002930 sirolimus Drugs 0.000 claims description 13
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 13
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 12
- 210000000845 cartilage Anatomy 0.000 claims description 11
- 210000002808 connective tissue Anatomy 0.000 claims description 11
- 210000004087 cornea Anatomy 0.000 claims description 11
- 210000001508 eye Anatomy 0.000 claims description 11
- 210000003709 heart valve Anatomy 0.000 claims description 11
- 210000000936 intestine Anatomy 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 11
- 210000005036 nerve Anatomy 0.000 claims description 11
- 210000000496 pancreas Anatomy 0.000 claims description 11
- 210000003786 sclera Anatomy 0.000 claims description 11
- 210000003491 skin Anatomy 0.000 claims description 11
- 210000002435 tendon Anatomy 0.000 claims description 11
- 210000001541 thymus gland Anatomy 0.000 claims description 11
- 210000004291 uterus Anatomy 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003018 immunosuppressive agent Substances 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 230000000139 costimulatory effect Effects 0.000 claims description 7
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 230000001400 myeloablative effect Effects 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 230000004144 purine metabolism Effects 0.000 claims description 7
- 210000003437 trachea Anatomy 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003761 preservation solution Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 289
- CHILCFMQWMQVAL-UHFFFAOYSA-N N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CHILCFMQWMQVAL-UHFFFAOYSA-N 0.000 description 209
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 198
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical class NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 description 177
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 156
- 108010036280 Aquaporin 4 Proteins 0.000 description 108
- 102100037276 Aquaporin-4 Human genes 0.000 description 108
- 206010030113 Oedema Diseases 0.000 description 103
- 239000008174 sterile solution Substances 0.000 description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- 239000011780 sodium chloride Substances 0.000 description 78
- 235000019445 benzyl alcohol Nutrition 0.000 description 66
- WSHXPHFIHYXZKC-UHFFFAOYSA-N [2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]-4-chlorophenyl] dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WSHXPHFIHYXZKC-UHFFFAOYSA-N 0.000 description 64
- 238000002347 injection Methods 0.000 description 63
- 239000007924 injection Substances 0.000 description 63
- 108010036221 Aquaporin 2 Proteins 0.000 description 59
- 102100034414 Aquaporin-2 Human genes 0.000 description 59
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 56
- 238000001356 surgical procedure Methods 0.000 description 51
- 239000008227 sterile water for injection Substances 0.000 description 46
- 238000001802 infusion Methods 0.000 description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 44
- 230000002265 prevention Effects 0.000 description 36
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- 230000003385 bacteriostatic effect Effects 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 24
- 150000001768 cations Chemical class 0.000 description 24
- 239000008121 dextrose Substances 0.000 description 24
- 150000003863 ammonium salts Chemical class 0.000 description 22
- 125000004429 atom Chemical group 0.000 description 22
- 239000008228 bacteriostatic water for injection Substances 0.000 description 22
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 20
- 102000006395 Globulins Human genes 0.000 description 18
- 108010044091 Globulins Proteins 0.000 description 18
- 239000008355 dextrose injection Substances 0.000 description 18
- 238000007913 intrathecal administration Methods 0.000 description 18
- 239000008354 sodium chloride injection Substances 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910001415 sodium ion Inorganic materials 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 14
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000007918 intramuscular administration Methods 0.000 description 13
- 229960000581 salicylamide Drugs 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- NNHMQZBVJPQCAK-UHFFFAOYSA-N 5-chloro-2-hydroxybenzamide Chemical compound NC(=O)C1=CC(Cl)=CC=C1O NNHMQZBVJPQCAK-UHFFFAOYSA-N 0.000 description 12
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 12
- 108010036949 Cyclosporine Proteins 0.000 description 12
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 125000002947 alkylene group Chemical group 0.000 description 12
- 230000001494 anti-thymocyte effect Effects 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 229960001265 ciclosporin Drugs 0.000 description 12
- 229930182912 cyclosporin Natural products 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 11
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical class CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 11
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 10
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 10
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 10
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 10
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 10
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 150000002780 morpholines Chemical class 0.000 description 10
- 150000004885 piperazines Chemical class 0.000 description 10
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 10
- 0 *c(cc1C(Nc2c(*)c(*)c(*)c(*)c2)=O)ccc1O* Chemical compound *c(cc1C(Nc2c(*)c(*)c(*)c(*)c2)=O)ccc1O* 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- FVWAGXROYQNHBV-UHFFFAOYSA-N Oc(cc1)cc(C(Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)=O)c1OP(O)(O)=O Chemical compound Oc(cc1)cc(C(Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)=O)c1OP(O)(O)=O FVWAGXROYQNHBV-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- 229960003459 allopurinol Drugs 0.000 description 6
- 230000000781 anti-lymphocytic effect Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 6
- 229960002170 azathioprine Drugs 0.000 description 6
- 229960004669 basiliximab Drugs 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 229940046731 calcineurin inhibitors Drugs 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 6
- 229960001076 chlorpromazine Drugs 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 229960002806 daclizumab Drugs 0.000 description 6
- 229960000958 deferoxamine Drugs 0.000 description 6
- 229940099217 desferal Drugs 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960005167 everolimus Drugs 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 229940050410 gluconate Drugs 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 229940050526 hydroxyethylstarch Drugs 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 6
- 229940099584 lactobionate Drugs 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 229960004584 methylprednisolone Drugs 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 229960005205 prednisolone Drugs 0.000 description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
- 229960004618 prednisone Drugs 0.000 description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 6
- 229960001967 tacrolimus Drugs 0.000 description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000002992 thymic effect Effects 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 5
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 5
- 108700027941 Celsior Proteins 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 5
- 229950007856 mofetil Drugs 0.000 description 5
- 229960000951 mycophenolic acid Drugs 0.000 description 5
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 5
- 239000000082 organ preservation Substances 0.000 description 5
- 238000002689 xenotransplantation Methods 0.000 description 5
- SNMUYHVTHLCYQT-UHFFFAOYSA-N 3-chloro-2-hydroxybenzamide Chemical compound NC(=O)C1=CC=CC(Cl)=C1O SNMUYHVTHLCYQT-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- OOYIYVJATNPAEY-UHFFFAOYSA-N C=[I]C(c1cc(C(F)(F)I)cc(NC(c(cc(cc2)Cl)c2OP(CCc2ccccc2)(OCc2ccccc2)=O)=O)c1)(F)F Chemical compound C=[I]C(c1cc(C(F)(F)I)cc(NC(c(cc(cc2)Cl)c2OP(CCc2ccccc2)(OCc2ccccc2)=O)=O)c1)(F)F OOYIYVJATNPAEY-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004888 Aquaporin 1 Human genes 0.000 description 2
- 108090001004 Aquaporin 1 Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NDDAQHROMJDMKS-XFYXLWKMSA-N [(2s,3s,5s,8r,9s,10s,13s,14s)-2-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]azanium;chloride Chemical compound Cl.C1[C@H](N)[C@@H](O)C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 NDDAQHROMJDMKS-XFYXLWKMSA-N 0.000 description 2
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N [O-][N+](c(cc1Cl)ccc1NC(c1cc(Cl)ccc1O)=O)=O Chemical compound [O-][N+](c(cc1Cl)ccc1NC(c1cc(Cl)ccc1O)=O)=O RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YCICLRBTJMLLGG-UHFFFAOYSA-N (2-chlorophenyl) dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1Cl YCICLRBTJMLLGG-UHFFFAOYSA-N 0.000 description 1
- UQCONOAQMLZQMP-IDIVVRGQSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;potassium;sodium Chemical compound [Na].[K].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UQCONOAQMLZQMP-IDIVVRGQSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical class CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150071538 AQP gene Proteins 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 102000004392 Aquaporin 5 Human genes 0.000 description 1
- 108090000976 Aquaporin 5 Proteins 0.000 description 1
- 102100029406 Aquaporin-7 Human genes 0.000 description 1
- 102100029463 Aquaporin-8 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000034706 Graft dysfunction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000771402 Homo sapiens Aquaporin-7 Proteins 0.000 description 1
- 101000771417 Homo sapiens Aquaporin-8 Proteins 0.000 description 1
- 101000771413 Homo sapiens Aquaporin-9 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229910003251 Na K Inorganic materials 0.000 description 1
- AYDZMKINCBJCDH-UHFFFAOYSA-N Nc(cc1C(Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)=O)ccc1OP(C=N)(O)=O Chemical compound Nc(cc1C(Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)=O)ccc1OP(C=N)(O)=O AYDZMKINCBJCDH-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000003855 acyl compounds Chemical class 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 210000002383 alveolar type I cell Anatomy 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 108010018755 aquaporin 0 Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000000162 organ preservation solution Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079541P | 2014-11-13 | 2014-11-13 | |
| US62/079,541 | 2014-11-13 | ||
| US201462080241P | 2014-11-14 | 2014-11-14 | |
| US62/080,241 | 2014-11-14 | ||
| PCT/US2015/060731 WO2016077787A1 (en) | 2014-11-13 | 2015-11-13 | Novel methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535546A JP2017535546A (ja) | 2017-11-30 |
| JP2017535546A5 true JP2017535546A5 (enExample) | 2018-12-20 |
Family
ID=55955168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525839A Withdrawn JP2017535546A (ja) | 2014-11-13 | 2015-11-13 | 新規な方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180042873A1 (enExample) |
| EP (1) | EP3218354A4 (enExample) |
| JP (1) | JP2017535546A (enExample) |
| CN (1) | CN107207417A (enExample) |
| AU (1) | AU2015346076A1 (enExample) |
| CA (1) | CA2966950A1 (enExample) |
| IL (1) | IL252086A0 (enExample) |
| SG (1) | SG11201703801SA (enExample) |
| TW (1) | TW201716059A (enExample) |
| WO (1) | WO2016077787A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102200176B1 (ko) | 2012-05-08 | 2021-01-11 | 에어로믹스, 인코포레이티드 | 신규 방법 |
| CN105899223A (zh) | 2013-10-28 | 2016-08-24 | 加利福尼亚大学董事会 | 转移性前列腺癌的治疗 |
| CN106163506A (zh) | 2013-11-06 | 2016-11-23 | 埃罗米克斯公司 | 新配方 |
| US11117909B2 (en) | 2016-05-13 | 2021-09-14 | Aeromics, Inc. | Crystals |
| CN110790787B (zh) * | 2019-11-12 | 2022-06-14 | 广东药科大学 | 一类水溶性前药、其制备方法及其作为药物的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263657B2 (en) * | 2000-12-18 | 2012-09-11 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
| CA2487900A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
| WO2003103656A1 (ja) * | 2002-06-06 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| BRPI0807918A2 (pt) * | 2007-02-17 | 2017-05-16 | Harvard College | composições e método para preservação de tecido |
| EP2201946A4 (en) * | 2007-10-23 | 2012-01-25 | Inst Med Molecular Design Inc | HAMMER OF PAI-1 PRODUCTION |
| WO2012125749A2 (en) * | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| KR102200176B1 (ko) * | 2012-05-08 | 2021-01-11 | 에어로믹스, 인코포레이티드 | 신규 방법 |
-
2015
- 2015-11-13 CA CA2966950A patent/CA2966950A1/en not_active Abandoned
- 2015-11-13 EP EP15859827.6A patent/EP3218354A4/en not_active Withdrawn
- 2015-11-13 AU AU2015346076A patent/AU2015346076A1/en not_active Abandoned
- 2015-11-13 WO PCT/US2015/060731 patent/WO2016077787A1/en not_active Ceased
- 2015-11-13 US US15/526,706 patent/US20180042873A1/en not_active Abandoned
- 2015-11-13 JP JP2017525839A patent/JP2017535546A/ja not_active Withdrawn
- 2015-11-13 CN CN201580073130.0A patent/CN107207417A/zh active Pending
- 2015-11-13 SG SG11201703801SA patent/SG11201703801SA/en unknown
-
2016
- 2016-05-18 TW TW105115290A patent/TW201716059A/zh unknown
-
2017
- 2017-05-03 IL IL252086A patent/IL252086A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020132220A1 (en) | Use of selectin antagonists in organ preservation solutions | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| JP2017535546A5 (enExample) | ||
| JP3287851B2 (ja) | ポルフィリンによる移植片生存の延長 | |
| JP2017535546A (ja) | 新規な方法 | |
| US20120064044A1 (en) | Methods of treating edema related to ischemia-reperfusion | |
| ES2363914T3 (es) | Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante. | |
| CA2896073C (en) | Stimulation and enhancement of regeneration of tissues | |
| US8809303B2 (en) | Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation | |
| CA3092596C (en) | Novel aminothiol reduction of ischemia-reperfusion-induced cell death | |
| JP6878418B2 (ja) | 移植片拒絶反応の処置方法 | |
| WO2002017959A2 (en) | Immunosuppression using piceatannol and a calcineurin inhibitor | |
| Monache et al. | Effect of pharmacological modulation of liver P-glycoproteins on cyclosporin A biliary excretion and cholestasis a study in isolated perfused rat liver | |
| LarijaniÇ | The role of Ischemia reperfusion damage on renal transplant, what are the new treatments? | |
| HK40031657A (en) | Novel aminothiol reduction of ischemia-reperfusion-induced cell death | |
| JP4638563B2 (ja) | 臓器移植障害予防治療剤 | |
| JP2022083279A (ja) | 腎臓保護用の組成物 | |
| JPH04327541A (ja) | 拒絶反応による移植臓器障害治療剤 | |
| JP2019522052A (ja) | 抗細菌組成物 | |
| WO2017021914A1 (en) | Abscisic acid for reducing damage to transplanted tissue | |
| WO2006035673A1 (ja) | 虚血性心臓傷害の新保護法 |